Results 41 to 50 of about 26,709,678 (285)

Effects of Cyclooxygenase Inhibitors on Apoptotic Neuroretinal Cells

Biomarker Insights, 2008
Glaucoma is characterized by a loss of retinal ganglion cells (RGC) which is associated with a decrease of visual function. Neuroprotective agents as a new therapeutic strategy could prevent the remaining neurons from apoptotic cell death.
Anja-Kristina Brust, Holger K. Ulbrich, Gail M. Seigel, Norbert Pfeiffer, Franz H. Grus   +4 more
doaj   +2 more sources

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

Molecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera, Laura Vela‐Martín, Pablo Fernández‐Navarro, José Luis López‐Lorenzo, Javier Cornago, Pilar Llamas, Eduardo Pérez‐Gómez, José Luis Marín‐Rubio, Manuel Fresno, Javier Santos, José Fernández‐Piqueras, María Villa‐Morales   +11 more
wiley   +1 more source

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

BMC Cancer, 2006
BackgroundEpidemiologic and laboratory investigations suggest that nonsteroidal anti-inflammatory drugs (NSAIDs) have chemopreventive effects against breast cancer due to their activity against cyclooxygenase-2 (COX-2), the rate-limiting enzyme of the ...
Randall Harris, Joanne Beebe-Donk, G. Alshafie   +2 more
semanticscholar   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Cyclooxygenase-2 inhibitors: promise or peril?

Mediators of Inflammation, 2002
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized ...
Laurel J. Mengle-Gaw, Benjamin D. Schwartz   +1 more
doaj   +1 more source

CARDIOVASCULAR EFFECTS OF SELECTIVE COX-2 INHIBITORS IN RHEUMATIC DISEASES

Современная ревматология, 2010
The paper gives data on the effects of nonsteroidal anti-inflammatory drugs on the cardiovascular system in patients with rheumatoid arthritis and osteoarthrosis.
Rimma Mikhailovna Balabanova
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials.

PLoS ONE, 2016
BackgroundEvidence on the benefits of combining cyclooxygenase-2 inhibitor (COX-2) in treating non-small cell lung cancer (NSCLC) is still controversial.
Yuan Yuan Zhou, Zhi Gang Hu, Fan Jun Zeng, Jiao Han   +3 more
doaj   +1 more source

Evolution of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Cyclooxygenase (COX) Inhibition and Beyond

Journal of Pharmacy & Pharmaceutical Sciences, 2008
Purpose. NSAIDs constitute an important class of drugs with therapeutic applications that have spanned several centuries. Treatment of inflammatory conditions such as rheumatoid arthritis (RA) and osteoarthritis (OA) starting from the classic drug ...
Praveen Rao, Edward E. Knaus
doaj   +1 more source

A comparison of the modified LANZA scores between those treated with COX-2-selective inhibitors and those treated with non-selective COX-1 and COX-2 inhibitors.

, 2018
(a) A comparison of the modified LANZA scores between patients treated with and without NSAIDs. (b) A comparison of the modified LANZA score between patients treated with COX-2-selective inhibitors and non-selective COX-1 and COX-2 inhibitors.
Yosuke Murata (440670), Yoshio Ozaki (5492771), Shosaku Nomura (541126), Tomoki Ito (5492777), Yasuaki Okuda (440674), Kazuo Jouyama (440675), Kenichiro Matoba (440671), Akihiro Yamada (440672), Saki Tsujimoto (5492774), Sho Mokuda (440669)   +9 more
core   +1 more source